NICE Recommends Three Drugs for Moderate-to-Severe Atopic Dermatitis

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Cibinqo (abrocitinib), Leo Pharma’s Adtralza (tralokinumab) and AbbVie’s Rinvoq (upadacitinib) for National Health Service (NHS) use in patients 12 years and older who have moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Patients need to have failed at least one systemic immunosuppressant or not be eligible for systemic immunosuppressants.

The recommendation was based on clinical trial evidence showing that all three drugs reduce symptoms of atopic dermatitis compared with placebo.

In April, NICE declined to recommend the treatments and said it needed to see more evidence of their cost-effectiveness.

Cibinqo costs more than $1,087 for a 28-pack of 100 mg or 200 mg tablets, Adtralza costs more than $1,301 for a 4-pack of 150 mg per 1 ml pre-filled syringe and Rinvoq costs more than $980 for a 28-pack of 15 mg modified-release tablets or more than $1,958 for a 28-pack of 30 mg modified-release tablets.

The negotiated prices for NHS use were not disclosed.